Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Cancer Drug Targets ; 13(1): 1-10, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22924417

RESUMO

Hyperforin is a prenylated phloroglucinol present in the medicinal plant St John's wort (Hypericum perforatum). The compound has many biological properties, including antidepressant, anti-inflammatory, antibacterial and antitumor activities. This review focuses on the in vitro antileukemic effects of purified hyperforin and related mechanisms in chronic lymphoid leukemia (CLL) and acute myeloid leukemia (AML) - conditions that are known for their resistance to chemotherapy. Hyperforin induces apoptosis in both CLL and AML cells. In AML cell lines and primary AML cells, hyperforin directly inhibits the kinase activity of the serine/threonine protein kinase B/AKT1, leading to activation of the pro-apoptotic Bcl-2 family protein Bad through its non-phosphorylation by AKT1. In primary CLL cells, hyperforin acts by stimulating the expression of the pro-apoptotic Bcl-2 family member Noxa (possibly through the inhibition of proteasome activity). Other hyperforin targets include matrix metalloproteinase-2 in AML cells and vascular endothelial growth factor and matrix metalloproteinase-9 in CLL cells - two mediators of cell migration and angiogenesis. In summary, hyperforin targets molecules involved in signaling pathways that control leukemic cell proliferation, survival, apoptosis, migration and angiogenesis. Hyperforin also downregulates the expression of P-glycoprotein, a protein that is involved in the resistance of leukemia cells to chemotherapeutic agents. Lastly, native hyperforin and its stable derivatives show interesting in vivo properties in animal models. In view of their low toxicity, hyperforin and its derivatives are promising antileukemic agents and deserve further investigation in vivo.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Leucemia Mieloide Aguda/tratamento farmacológico , Floroglucinol/análogos & derivados , Terpenos/farmacologia , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Animais , Antineoplásicos Fitogênicos/efeitos adversos , Antineoplásicos Fitogênicos/uso terapêutico , Apoptose/efeitos dos fármacos , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Leucemia Linfocítica Crônica de Células B/enzimologia , Leucemia Linfocítica Crônica de Células B/metabolismo , Leucemia Mieloide Aguda/enzimologia , Leucemia Mieloide Aguda/metabolismo , Leucócitos/efeitos dos fármacos , Leucócitos/enzimologia , Leucócitos/metabolismo , Proteínas de Neoplasias/antagonistas & inibidores , Floroglucinol/efeitos adversos , Floroglucinol/farmacologia , Floroglucinol/uso terapêutico , Complexo de Endopeptidases do Proteassoma/efeitos dos fármacos , Complexo de Endopeptidases do Proteassoma/metabolismo , Inibidores de Proteínas Quinases/efeitos adversos , Inibidores de Proteínas Quinases/farmacologia , Inibidores de Proteínas Quinases/uso terapêutico , Proteínas Proto-Oncogênicas c-akt/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-akt/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Transdução de Sinais/efeitos dos fármacos , Terpenos/efeitos adversos , Terpenos/uso terapêutico
2.
Biochem Pharmacol ; 78(5): 514-22, 2009 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-19433065

RESUMO

CD80/B7.1 expressed on monocytes plays a prominent role in the activation of T cell-mediated immunity and its level is reduced in monocytes from cancer patients. Type I (alpha/beta) and type II (gamma) IFNs are widely administered as adjuvant therapy. We show here that both classes of IFNs upregulate CD80 mRNA and protein in primary monocytes ex vivo. The stimulatory action of IFN-alpha/beta on CD80 is accompanied by the activation of both interferon regulatory factors IRF-1 and IRF-7, whereas IFN-gamma stimulating effect is associated only with IRF-1 induction. IFNs concomitantly upregulate the transcription of CD40 costimulatory molecule whose activation is known to require IRF-1. In monocytic U937 cells, IRF-1 is activated by IFN-gamma but not by IFN-alpha/beta, whereas it is the reverse for IRF-7; in the latter cells, only IFN-gamma is capable of stimulating CD80 transcription emphasizing the essential role of IRF-1. Moreover, siRNA against IRF-1 prevents IFN-gamma-mediated CD80 activation. In AML cells, IFNs upregulate CD40, CD80 and IRF-1 in the FAB-M4/M5 subtypes but not in the less differentiated M1/M2 subtypes. Monitoring the expression of CD80 on AML cells and its modulation by IFNs could help to predict the patients more susceptible to benefit from therapeutic strategies aimed at eliciting specific T cell responses to leukemia-associated antigens.


Assuntos
Antígeno B7-1/fisiologia , Fator Regulador 1 de Interferon/fisiologia , Interferon Tipo I/fisiologia , Interferon gama/fisiologia , Monócitos/metabolismo , Regulação para Cima/fisiologia , Sequência de Bases , Primers do DNA , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Reação em Cadeia da Polimerase Via Transcriptase Reversa
3.
Oncogene ; 26(1): 102-10, 2007 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-16799629

RESUMO

The transmembrane metalloproteases angiotensin-converting enzyme (ACE) and tumor necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE/ADAM-17) have been associated with inflammation, cancer progression and angiogenesis. Few investigations into the regulation of these enzymes by physiological stimuli have been reported. In this study, we investigated the influence of interferons (IFNs) type I (alpha, beta) and II (gamma) on ACE and TACE expression of human leukemic NB4 cells and monocytes. We assessed the expression of proteases by reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay and immunofluorescence analyses. IFNgamma, but not type I IFNs, upregulated membrane ACE in a dose- and time-dependency and this was reflected by the increase of ACE enzymatic activity and ACE mRNA. ACE upregulation was dependent on protein synthesis. Treatment of the interferon responsive factor 1 (IRF1)-unresponsive HepG2 cell line with IFNgamma did not affect ACE expression, thus suggesting the participation of the IRF1 signaling pathway in IFNgamma-mediated ACE upregulation in myeloid cells. In contrast, both types of IFNs, in a dose- and time-dependent manner, downregulated surface TACE without affecting TACE transcript. Soluble TACE was not detected in the medium of IFN-treated cells. IFNgamma-mediated decrease of surface TACE in NB4 cells was reversible, and correlated with an increase in intracellular TACE, suggesting that cell surface TACE was internalized in response to IFNs. These findings, showing the presence of IFN-dependent controlled mechanisms by which ACE and TACE levels are regulated in human normal and leukemic myeloid cells, may have implications in the context of current investigations on the therapeutic potential of IFNs.


Assuntos
Proteínas ADAM/metabolismo , Interferon Tipo I/fisiologia , Interferon gama/fisiologia , Leucemia Mieloide/enzimologia , Monócitos/enzimologia , Peptidil Dipeptidase A/metabolismo , Proteína ADAM17 , Sequência de Bases , Western Blotting , Linhagem Celular Tumoral , Cicloeximida/farmacologia , Primers do DNA , Ensaio de Imunoadsorção Enzimática , Humanos , Leucemia Mieloide/patologia , Monócitos/metabolismo , Reação em Cadeia da Polimerase , Regulação para Cima/efeitos dos fármacos
4.
Cell Mol Biol (Noisy-le-grand) ; 52(1): 51-8, 2006 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-16914095

RESUMO

Matrix metalloproteinase-9 is involved in inflammation and tumor progression. We previously demonstrated that interferon type I (alpha/beta) and II (gamma) inhibit matrix metalloproteinase-9 (92kDa) gene expression on lymphocytes from patients with B chronic lymphocytic leukemia and human monocytes. Since all-trans retinoic acid (ATRA) can regulate some interferon -responsive genes, we studied here the effects of all-trans retinoic acid onto matrix metalloproteinase-9 levels in these cells. By using RT-PCR, ELISA and zymography experiments, we showed that all-trans retinoic acid down-regulated matrix metalloproteinase-9 synthesis (mRNA,protein) and secretion. The inhibitory action of all-trans retinoic acid toward matrix metalloproteinase-9 was however not associated with the STAT1/IRF-1 pathway involved in interferon-mediated matrix metalloproteinase-9 inhibition indicating that all-trans retinoic acid did not bypass IFN receptor signaling. Using flow cytometry, we detected on the surface of monocytes low expression of matrix metalloproteinase-9 and Fc-gammaRI, and high expression of HLA-DR, beta1 and beta2 integrins. Enhancement of Fc-gammaRI and HLA-DR on monocytes by interferon-gamma, but not by all-trans retinoic acid, was accompanied by up-regulation of surface matrix metalloproteinase-9. Furthermore, we showed that all-trans retinoic acid down-regulated matrix metalloproteinase-9 expression in lymphocytes of untreated patients with early stage B chronic lymphocytic leukemia. Together, our data suggest the potential relevance of all-trans retinoic acid as a pharmacological tool to attenuate matrix metalloproteinase-9 secretion in pathological situations.


Assuntos
Antígenos de Superfície/metabolismo , Interferon gama/farmacologia , Metaloproteinase 9 da Matriz/metabolismo , Monócitos/metabolismo , Tretinoína/farmacologia , Linfócitos B/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Perfilação da Expressão Gênica , Humanos , Fator Regulador 1 de Interferon/metabolismo , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Leucemia Linfocítica Crônica de Células B/metabolismo , Metaloproteinase 9 da Matriz/biossíntese , Transporte Proteico/efeitos dos fármacos , Fator de Transcrição STAT1/metabolismo , Distribuição Tecidual/efeitos dos fármacos , Células Tumorais Cultivadas , Fator de Necrose Tumoral alfa/metabolismo
5.
J Clin Virol ; 27(1): 59-68, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12727530

RESUMO

BACKGROUND: Dipeptidyl peptidase IV is a transmembrane enzyme widely expressed in many cell types, but also present as a soluble form in biological fluids. Its abnormal activity is sometimes associated with liver disease related pathologies. OBJECTIVES: The aim of this study was to evaluate the clinical relevance of changes in serum DPPIV activity in hepatitis C and other viral infections. STUDY DESIGN: DPPIV activity was assessed by using a microplate-based colorimetric assay on serum from 88 subjects: 12 healthy uninfected controls, 10 patients with primary biliary cirrhosis (PBC) as a reference group, 36 HCV-infected patients, and patients suffering from viral infections of different etiologies. Levels of DPPIV activity were compared with: (1) those of other serum biochemical parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transpeptidase (GGT), and bilirubin concentrations; and (2) criteria representative of liver histological status. RESULTS: Compared with healthy subjects, DPPIV activity was significantly increased during viral infections and in PBC (P<0.01). In HCV-infected patients, the median activity (interquartile range, IQR), 29.78 IU/l (24.66-35.95), differed significantly (P<0.05) from that of controls: 21.42 (19.76-24.93). No correlation was observed between DPPIV activity and either ALT, AST, bilirubin, or the stage of liver fibrosis and necroinflammatory activity, although GGT was moderately correlated (r=0.58, P<0.05). CONCLUSIONS: Although we confirmed an elevation of serum DPPIV activity in PBC, it seems to be a non-specific phenomenon common to viral infections. The absence of correlation between serum DPPIV and markers of liver disease in HCV-infected patients, suggests that this activity originates not only from the liver, but also from other sources such as peripheral blood cells involved in the control of viral infections.


Assuntos
Dipeptidil Peptidase 4/sangue , Hepatite C Crônica/enzimologia , Viroses/enzimologia , Adulto , Colestase/enzimologia , Colestase/fisiopatologia , Progressão da Doença , Feminino , Hepatite C Crônica/patologia , Hepatite C Crônica/fisiopatologia , Hepatite C Crônica/virologia , Humanos , Fígado/patologia , Fígado/virologia , Cirrose Hepática Biliar/enzimologia , Cirrose Hepática Biliar/patologia , Masculino , Pessoa de Meia-Idade , Viroses/patologia , Viroses/fisiopatologia , Viroses/virologia
6.
Leukemia ; 16(5): 791-8, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11986939

RESUMO

Besides vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), matrix metalloproteinases (MMPs) play critical roles in angiogenesis, tumor invasion and metastasis. Increased angiogenesis is observed in chronic B lymphocytic leukemia (B-CLL) and published data reported VEGF and bFGF production in this disease. The purpose of this study was to investigate MMP expression in early stage B-CLL. Elevated MMP-9 concentrations were detected by ELISA in the sera of B-CLL patients (median level 250 ng/ml) compared with healthy donors (67 ng/ml) (P < 0.0001), and immunostaining with antibodies against MMP-9 and B cell antigens (CD19, CD23) substantiated the presence of MMP-9 in tumoral B lymphocytes. By using RT-PCR, ELISA and zymography experiments, we confirmed that B-CLL cells expressed and released the pro-form of MMP-9 with Mr 92 kDa (158-1300 pg/ml/10(6) cells/48 h), p-aminophenylmercuric acetate generating a 82 kDa active form. In contrast, the production of MMP-9 by normal counterpart B cells was significantly low (28-169 pg/ml/10(6)cells/48 h). Moreover, B-CLL culture supernatants contained bFGF (median levels 17 pg/ml/10(6) cells/48 h), VEGF (1.4 pg/ml/10(6) cells/48 h) and TNF-alpha (0.2 pg/ml/10(6) cells/48 h). TNF-alpha and VEGF antibodies blocked MMP-9 at the mRNA and protein levels. Interferons (IFNs) type I or type II repressed MMP-9 gelatinolytic activity in a dose and time dependency, and this was reflected by a parallel inhibition of MMP-9 mRNA and protein. IFNs however did not affect the production of bFGF, VEGF and TNF-alpha. Together, our data show that B-CLL lymphocytes synthesize MMP-9 and emphasize the specific inhibitory actions of IFNs on its expression.


Assuntos
Leucemia Linfocítica Crônica de Células B/enzimologia , Metaloproteinase 9 da Matriz/biossíntese , Estudos de Casos e Controles , Técnicas de Cultura de Células , Meios de Cultura/química , Meios de Cultura/metabolismo , Fatores de Crescimento Endotelial/metabolismo , Fatores de Crescimento Endotelial/farmacologia , Fator 2 de Crescimento de Fibroblastos/efeitos dos fármacos , Fator 2 de Crescimento de Fibroblastos/metabolismo , Humanos , Interferon Tipo I/farmacologia , Interferon-alfa/farmacologia , Interferon gama/farmacologia , Leucemia Linfocítica Crônica de Células B/patologia , Linfocinas/efeitos dos fármacos , Linfocinas/metabolismo , Linfocinas/farmacologia , Metaloproteinase 9 da Matriz/sangue , Inibidores de Metaloproteinases de Matriz , Fator de Necrose Tumoral alfa/farmacologia , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular
7.
FEBS Lett ; 508(2): 226-30, 2001 Nov 16.
Artigo em Inglês | MEDLINE | ID: mdl-11718720

RESUMO

The inhibitor of gamma-glutamyl transpeptidase (gamma-GT) acivicin modulates cellular responses including growth, myeloid maturation and apoptosis. Whether these effects result from the inhibition of gamma-GT enzyme activity remains unclear. We compared the cellular effects of acivicin against a more potent and specific inhibitor of gamma-GT (L-2-amino-4-boronobutanoic acid (L-ABBA)) in gamma-GT-negative (B lymphoblastoid Ramos) and gamma-GT-positive (myelomonocytic HL-60, gamma-GT-transfected Ramos) cell lines. Under non-oxidative stress conditions, acivicin-induced cell growth arrest, apoptosis and macrophage maturation occurred independent of gamma-GT while L-ABBA did not influence any of these processes. Acivicin triggered tyrosine phosphorylation and increased nuclear factor kappaB activity. Further insight into the role of gamma-GT in cellular processes is needed.


Assuntos
Apoptose/efeitos dos fármacos , Compostos de Boro/farmacologia , Isoxazóis/farmacologia , Macrófagos/efeitos dos fármacos , gama-Glutamiltransferase/antagonistas & inibidores , gama-Glutamiltransferase/metabolismo , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Genisteína/farmacologia , Células HL-60 , Humanos , Macrófagos/citologia , NF-kappa B/metabolismo , Espectrometria de Fluorescência , Transfecção , Tirfostinas/farmacologia , gama-Glutamiltransferase/genética
8.
Bioorg Med Chem ; 9(11): 2843-8, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11597464

RESUMO

Acivicin is an antitumor agent known to inhibit cell growth. A new prodrug 9b of acivicin 10 was synthesized, based on a p-hydroxybenzylcarbamate self-immolative spacer capable to release acivicin under esterase activity. The prodrug includes a maleimide-containing arm for linkage with thiol-containing macromolecules such as antibodies. This molecule is intended for the conception of bioconjugates to target an inactive acivicin precursor to tumor cells, when linked to a monoclonal antibody (mAb) which recognizes a tumor-specific antigen. Prodrug cleavage by plasmatic esterases will then restore the acivicin's activity toward tumor cells. We report here the synthesis and the in vitro characteristics of the prodrug. As expected, its inhibitory activity against the gamma-glutamyl transpeptidase (gamma-GT) enzyme and its cytotoxicity towards HL-60 cells were highly reduced compared to the parent drug. The chemical and plasmatic hydrolysis kinetics of the compound was studied by HPLC. The prodrug is stable, being slowly hydrolyzed in pH 7.6 buffer at 37 degrees C with a half-life of 37 h. It is converted into an active acivicin under the effect of pig liver esterase, and its half-life in human plasma is 3 h. These results indicate this compound may be further used as a prodrug-antibody conjugate, to target acivicin to malignant cells.


Assuntos
Antineoplásicos/síntese química , Antineoplásicos/farmacocinética , Isoxazóis/farmacocinética , Pró-Fármacos/síntese química , Animais , Antineoplásicos/química , Divisão Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Cromatografia Líquida de Alta Pressão , Sistemas de Liberação de Medicamentos , Desenho de Fármacos , Estabilidade de Medicamentos , Esterases/metabolismo , Células HL-60/efeitos dos fármacos , Meia-Vida , Humanos , Concentração Inibidora 50 , Isoxazóis/síntese química , Isoxazóis/química , Fígado/enzimologia , Pró-Fármacos/química , Pró-Fármacos/farmacocinética , Suínos , gama-Glutamiltransferase/antagonistas & inibidores
9.
J Biol Regul Homeost Agents ; 15(2): 130-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11501970

RESUMO

Transmembrane proteases (i.e. membrane-associated proteases, ectoproteases) are present in a wide variety of tissues and cell types including endothelial, epithelial and hematopoietic cells. Natural and synthetic inhibitors have been characterized and have revealed that certain ectoenzymes are able to modulate bioactive peptide responses and to influence major biological events such as cell proliferation, survival and invasiveness. Dysregulated expression of some of them in human diseases triggers research on their role in pathophysiology, on their value as disease markers and as putative targets for therapy.


Assuntos
Membrana Celular/enzimologia , Endopeptidases/metabolismo , Animais , Biomarcadores , Desenho de Fármacos , Humanos , Técnicas In Vitro , Neoplasias/tratamento farmacológico , Neoplasias/enzimologia , Inibidores de Proteases/farmacologia
10.
J Control Release ; 74(1-3): 255-7, 2001 Jul 06.
Artigo em Inglês | MEDLINE | ID: mdl-11489503

RESUMO

The ectopeptidase gamma-glutamyltranspeptidase (gamma-GT) is overexpressed in myeloid leukemias. Its specific inhibitor, acivicin, was previously shown to induce an inhibitory growth effect associated with an induction of morphological features characteristic of macrophage maturation. We have considered a construction in which an antibody linked to a prodrug of acivicin will target acivicin to tumoral cells. In a first set of experiments we have synthesized a chromogenic model of this prodrug to validate this concept of prodrug, allowing an amine function to be released upon esterase action. Thereafter this model was applied to acivicin. The acivicin prodrug is inactive toward purified gamma-GT, and recovers its inhibitory activity under the effect of esterase.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Antibióticos Antineoplásicos/farmacocinética , Imunoconjugados/administração & dosagem , Imunoconjugados/farmacocinética , Isoxazóis/administração & dosagem , Isoxazóis/farmacocinética , Pró-Fármacos , gama-Glutamiltransferase/química , Antibióticos Antineoplásicos/química , Carbamatos/química , Esterases/química , Hidrólise , Imunoconjugados/química , Isoxazóis/química , Modelos Químicos , Pró-Fármacos/química , Espectrofotometria Ultravioleta
11.
J Leukoc Biol ; 70(1): 11-7, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11435480

RESUMO

Recent advances have led to the identification and characterization of an array of transmembrane proteases that mediate the proteolysis of various substrates (including bioactive peptides, components of the extracellular matrix, and integral proteins) and cell-cell or cell-matrix adhesion. The membrane proteases known to participate in these processes currently include the ectopeptidases, the membrane-type matrix metalloproteases (MT-MMPs), the ADAM (a disintegrin and metalloprotease) family, the meprins, and the secretases, and this list may be expected to grow. The roles that these molecules play within neoplastic and inflammatory sites are being investigated actively. The capacity of these ectoenzymes to transmit intracellular-transduction signals through the plasma membrane has to be considered. An appreciation of their functional redundancy is emerging.


Assuntos
Proteínas de Membrana/fisiologia , Metaloendopeptidases/fisiologia , Serina Endopeptidases/fisiologia , Animais , Humanos , Proteínas de Membrana/química , Metaloendopeptidases/química , Serina Endopeptidases/química
12.
Bioessays ; 23(3): 251-60, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11223882

RESUMO

Ectopeptidases are transmembrane proteins present in a wide variety of tissues and cell types. Dysregulated expression of certain ectopeptidases in human malignancies suggests their value as clinical markers. Ectopeptidase interaction with agonistic antibodies or their inhibitors has revealed that these ectoenzymes are able to modulate bioactive peptide responses and to influence growth, apoptosis and differentiation, as well as adhesion and motility, all functions involved in normal and tumoral processes. There is evidence that ectopeptidase-mediated signal transduction frequently involves tyrosine phosphorylation. Combined analyses of gene organization and regulation of ectopeptidases by various physiological factors have provided insights into their structure-function relationships. Understanding the roles of ectopeptidases in pathophysiology may have implications in considering them as therapeutic targets.


Assuntos
Exopeptidases/genética , Exopeptidases/metabolismo , Doenças do Sistema Imunitário/enzimologia , Neoplasias/enzimologia , Transformação Celular Neoplásica , Mapeamento Cromossômico , Cromossomos Humanos , Neoplasias Hematológicas/enzimologia , Neoplasias Hematológicas/genética , Humanos , Doenças do Sistema Imunitário/genética , Neoplasias/genética , Transdução de Sinais
14.
Oncogene ; 19(2): 265-72, 2000 Jan 13.
Artigo em Inglês | MEDLINE | ID: mdl-10645005

RESUMO

Interferons (IFNs alpha, beta and gamma) and all trans retinoic acid (RA) have the ability to activate genes with GAS sites. We have found that the promoter of CD26/dipeptidylpeptidase IV (DPPIV) contains a consensus GAS site TTCnnnGAA located at bp-35 to -27, and computer analysis confirmed this sequence to be a putative Stat binding site. Consistent with this finding, we show that IFNs and RA rapidly enhanced CD26 gene and protein expression in chronic B lymphocytic leukemia (B-CLL) cells. Immunoblot analyses revealed that unstimulated B-CLL cells expressed detectable levels of serine/tyrosine-phosphorylated Stat1alpha, and RA and IFN-gamma treatment led to increased levels of tyrosine phosphorylation of Stat1alpha and its nuclear accumulation. As shown by electrophoretic mobility shift assay, RA and IFN-gamma increased the binding of a nuclear protein to the GAS-CD26 element. Shift-Western blotting identified Stat1alpha as the GAS-CD26 binding factor. Augmented levels of CD26 protein in malignant B cells cultured with IFNs or RA coincided with the enhancement of DPPIV activity. Taken together, our results are in favor of the IFN-/RA-mediated upregulation of CD26/DPPIV in B-CLL through the signaling pathway involving Stat1alpha and the GAS response element of CD26 promoter.


Assuntos
Dipeptidil Peptidase 4/biossíntese , Dipeptidil Peptidase 4/genética , Regulação Neoplásica da Expressão Gênica , Interferons/fisiologia , Leucemia de Células B/genética , Tretinoína/fisiologia , Separação Celular , Proteínas de Ligação a DNA/genética , Proteínas de Ligação a DNA/metabolismo , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Fator Regulador 1 de Interferon , Fator Gênico 3 Estimulado por Interferon , Interferon gama/farmacologia , Leucemia de Células B/metabolismo , Fosfoproteínas/genética , Fosfoproteínas/metabolismo , Fosforilação , Regiões Promotoras Genéticas/efeitos dos fármacos , Regiões Promotoras Genéticas/genética , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Fatores de Transcrição/metabolismo , Células Tumorais Cultivadas , Tirosina/metabolismo
15.
Hematol J ; 1(3): 172-80, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11920186

RESUMO

INTRODUCTION: Modulation of the adhesive responses of monocytic cells may reflect their motility within the bone marrow and at sites of inflammation. Monocyte alpha5beta1 integrins mediate fibronectin-dependent adhesion. We previously showed that type II IFN-gamma reduces adhesiveness to fibronectin (Fn) whereas TGF-beta1 enhances cell attachment. Here, we investigate the role of type I IFNs (alpha, beta) on the adhesive capacity of monocytic cells. MATERIALS AND METHODS: The influence of IFNs on the human U937 cell line adhesion to fibronectin-coated surfaces was determined. The expression of integrins and cytoskeleton proteins was analyzed by FACS, Western blotting and/or fluorescence microscopy analyses. RESULTS: IFN-alpha did not affect cell adhesion to fibronectin. In contrast, IFN-beta, like IFN-gamma, abrogated U937 adhesion to fibronectin and antagonized TGF-beta1-mediated cell attachment to Fn. The impaired binding of IFN-beta- and IFN-gamma-treated cells to fibronectin was not due to reduced levels of alpha5beta1 integrins. IFN-beta and IFN-gamma re-organized filamentous actin, and such rearrangement differed from that observed in TGF-beta1-adhesive cells. U937 cells dominantly expressed 44 to 46 kDa paxillin forms and treatment with IFNs enhanced the number of 66 to 70 kDa forms of paxillin. CONCLUSION: Our data show that IFN-beta and IFN-gamma induced loss of monocytic adhesion to fibronectin associated with changes in actin and paxillin cytoskeleton, thereby pointing to a possible effect of these cytokines in monocyte trafficking.


Assuntos
Adesão Celular/efeitos dos fármacos , Proteínas do Citoesqueleto/fisiologia , Fibronectinas/fisiologia , Interferon-alfa/farmacologia , Interferon beta/farmacologia , Interferon gama/farmacologia , Monócitos/citologia , Receptores de Fibronectina/fisiologia , Fator de Crescimento Transformador beta/farmacologia , Actinas/fisiologia , Northern Blotting , Citometria de Fluxo , Humanos , Interferon alfa-2 , Monócitos/efeitos dos fármacos , Paxilina , Fosfoproteínas/fisiologia , Receptores de Fibronectina/genética , Proteínas Recombinantes , Células U937
16.
J Interferon Cytokine Res ; 19(9): 1059-66, 1999 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10505750

RESUMO

The activation antigen CD38, which has NAD+ glycohydrolase activity in its extracellular domain, is expressed by a large variety of cell types. Few investigations into the regulation of CD38 expression by physiologic stimuli have been reported. As the CD38 promoter contains potential binding sites for interferon (IFN) regulatory factor-1 (IRF-1), we investigated the influence of IFN type I (alpha and beta) and type II (gamma) on CD38 gene expression of leukemic B cells. Using the IFN-responsive B cell line Eskol, we found by RT-PCR analysis a rapid time-dependent induction in CD38 mRNA (starting at 6 h) with each type of IFN. This induction was independent of protein synthesis, suggesting that CD38 gene activation does not require IRF-1 but is merely under direct transcriptional regulation by latent IFN-inducible factors. mRNA stimulation was followed within 24 h by induction of membrane CD38, which coincided with rises of CD38-specific ectoenzymatic activities, that is, NAD+ glycohydrolase, (A/G)DP-ribosyl cyclase, and cyclic ADP ribose hydrolase activities. IFN failed to induce or upregulate the other CD38-related ectoenzymes analyzed, that is, CD39, CD73, CD157, and PC-1. Similarly, treatment of leukemic cells of patients with B chronic lymphocytic leukemia (B-CLL) with IFN resulted in an increase in CD38 mRNA mirrored by plasma membrane upregulation of CD38 and NAD+ glycohydrolase activity. Further investigation in relation to CD38 gene activation and B-CLL behavior remains to be defined.


Assuntos
Antígenos CD , Antígenos de Diferenciação/genética , Antineoplásicos/farmacologia , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Interferon Tipo I/farmacologia , Interferon gama/farmacologia , Leucemia de Células Pilosas/metabolismo , NAD+ Nucleosidase/genética , ADP-Ribosil Ciclase , ADP-Ribosil Ciclase 1 , Linfócitos B/efeitos dos fármacos , Linfócitos B/metabolismo , Proteínas de Ligação a DNA/metabolismo , Ensaios de Seleção de Medicamentos Antitumorais , Células HL-60 , Humanos , Fator Regulador 1 de Interferon , Interferon gama/metabolismo , Leucemia de Células Pilosas/imunologia , Glicoproteínas de Membrana , Fosfoproteínas/metabolismo , Regiões Promotoras Genéticas , Transdução de Sinais/fisiologia , Ativação Transcricional , Células Tumorais Cultivadas , Regulação para Cima
17.
Br J Cancer ; 79(7-8): 1042-8, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10098734

RESUMO

We have investigated the expression of the ectoenzyme dipeptidylpeptidase IV (DPP IV)/CD26 on lymphocytes obtained from patients with B chronic lymphocytic leukaemia (B-CLL) and compared it with healthy subjects. Using two-colour immunofluorescence analysis with CD26 and CD20 or CD23 monoclonal antibodies, CD26 was found undetectable on peripheral resting B-cells (CD20+ CD23-) from normal donors whereas it was expressed on B-cells activated in vitro with interleukin (IL)-4 and Staphylococcus aureus strain cowan I (CD20+ CD23+). The expression of CD26 on leukaemic B-cells (CD20+ CD23+) was clearly induced in 22 out of 25 patients examined. Consequently, induced levels of CD26 cell surface expression on either normal activated and malignant B-cells coincided with the enhancement of DPP IV activity detected on the surface of these cells. Reverse transcription polymerase chain reaction analyses showed that the transcript levels of the CD26 gene was higher in normal activated B-cells and B-CLL cells than in resting B-cells, suggesting that CD26 was expressed at the level of transcriptional activation. These observations provide evidence of the abnormal expression of DPPIV/CD26 in B-CLL which, therefore, may be considered as a novel marker for B-CLL. Further investigation in relation to CD26 expression and other B malignancies needs to be defined.


Assuntos
Antígenos de Superfície/metabolismo , Linfócitos B/metabolismo , Dipeptidil Peptidase 4/metabolismo , Leucemia Linfocítica Crônica de Células B/metabolismo , Adulto , Imunofluorescência , Humanos , Leucemia Linfocítica Crônica de Células B/imunologia , Reação em Cadeia da Polimerase
18.
Biochimie ; 80(8-9): 739-44, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9865496

RESUMO

Human hydatidosis is characterized by a prolonged coexistence of parasite (Echinococcus granulosus) and host without effective rejection. The basis of the immune response of the patient is poorly understood. Previously, we reported the presence of IFN, TNF-alpha and IL-6 activities in the serum of patients with liver and lung hydatidosis. In the present work, we have investigated the production of nitrite (NO2-) in the serum of hydatidic patients carrying hepatic and pulmonary cysts (range 36-300 microM). Our present data show a correlation between the production of nitrite + nitrate (NO2- + NO3-) and that of circulating cytokines IFN and IL-6. In relapsing patients who did not produce IFN and IL-6, the observed serum NO2- concentrations were low (range 10-37.2 microM), as compared to those detected in patients before surgery. Induction of NO synthase in leukocytes from hydatidic patients was induced by stimulating these cells with a specific parasitic antigen, Antigen-5, as assessed by the increased levels of NO3- + NO2- in the range of 60-85 microM for patients with liver hydatidosis, as compared to the 20-25 microM detected in healthy controls. Collectively, our data indicate that NO2- + NO3- levels correlate with IFN levels and immunoreactivity, and overall suggest that IFN-gamma and nitric oxide production together play a role in the host defense mechanisms in human hydatidosis.


Assuntos
Equinococose/metabolismo , Interferon gama/biossíntese , Óxido Nítrico/metabolismo , Nitritos/metabolismo , Adulto , Animais , Antígenos de Helmintos/imunologia , Feminino , Humanos , Interleucina-6/sangue , Leucócitos Mononucleares , Masculino , Fator de Necrose Tumoral alfa/análise
19.
Leukemia ; 11(4): 552-60, 1997 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9096696

RESUMO

A role for IgG molecules in the activation of human myelogenous leukemia cells was examined. When added to monoblastic (U937) leukemia cells, mouse (m)IgG1 produced a dose- and time-dependent inhibitory growth effect associated with the induction of morphological features characteristic of macrophage maturation, and enhanced surface expression of Mac-1/CD11b characteristic of monocyte development. A study of isotype dependency of mig indicated that the effect was specific for Ig molecules of the IgG1 and IgG2b subclasses, whereas IgG2a or IgM had no effect. In parallel to U937 cell maturation, a marked production of latent TGF-beta was observed in supernatants of leukemia cells cultured with mIgG1. Myeloblastic (HL-60) leukemia cell line similarly responded to mIgG1 or mIgG2b in induction of macrophage differentiation and in the absence of neutrophil differentiation. Human blood monocytes cultured in the presence of mIgG1, exhibited higher levels of IL-1 beta and IL-6 mRNAs associated with an increase in protein extracellular release, suggesting that the effect of mIgG1 on IL-1 beta and IL-6 production in human monocytes was mediated at both transcriptional and post-transcriptional levels. Monocyte activation by mIgG1 and mIgG2b was associated with increased cell surface expression of HLA-DR class II molecules. Human IgG1 (and to a lesser degree hIgG2), was also capable of inducing leukemia cell growth arrest and macrophage maturation whereas F(ab')2 fragments of mIgG1 were not as efficient as intact mIgG1 in blocking cell growth. Most importantly, mAbs reactive with Fc gamma RII (CD32-specific Abs 2E.1 and IV.3) blocked the effects of mIgG1 on leukemia cell proliferation. Taken together, these data indicate that binding of IgG1 molecules, possibly through Fc gamma RII, may generate an activation signal towards myelogenous leukemia cells and normal counterpart cells, ie monocytes, leading to induction of macrophage maturation and cytokine secretion.


Assuntos
Citocinas/biossíntese , Imunoglobulina G/farmacologia , Leucemia Mieloide/imunologia , Ativação de Macrófagos , Monócitos/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Divisão Celular , Linhagem Celular/efeitos dos fármacos , DNA de Neoplasias/biossíntese , Humanos , Fragmentos Fab das Imunoglobulinas/farmacologia , Monócitos/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...